{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:30:49Z","timestamp":1786995049306,"version":"build-2736575974"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neuroscience.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T06:57:55Z","timestamp":1757660275000},"page":"429-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A review of the TGF-\u03b21 pathway in Alzheimer\u2019s disease and depression: Possible restoration potential of antidepressants"],"prefix":"10.1016","volume":"585","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3854-2217","authenticated-orcid":false,"given":"Ioannidou","family":"Eleni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vavilis","family":"Theofanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bourtzos","family":"Zisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-821X","authenticated-orcid":false,"given":"Stamoula","family":"Eleni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2025.09.010_b0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Alzheimer\u2019s disease neuroimaging initiative, 2018 Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer\u2019s dementia in individuals with previous depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.01.002","article-title":"Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients","volume":"123","author":"Basso","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49596-0","article-title":"Adult microglial TGF\u03b21 is required for microglia homeostasis via an autocrine mechanism to maintain cognitive function in mice","volume":"15","author":"Bedolla","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0000000000207379","article-title":"What are the roles of pericytes in the neurovascular unit and its disorders?","volume":"100","author":"Benarroch","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/pcn.12604","article-title":"Neural basis of major depressive disorder: beyond monoamine hypothesis","volume":"72","author":"Boku","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0035","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.3390\/ijms25126542","article-title":"Emerging therapeutic potential of fluoxetine on cognitive decline in Alzheimer\u2019s disease: systematic review","volume":"25","author":"Bougea","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0040","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1874467211104020141","article-title":"Inhibitory Smad7: emerging roles in health and disease","volume":"4","author":"Briones-Orta","year":"2011","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0896-6273(03)00766-9","article-title":"Loss of TGF-\u03b21 leads to increased neuronal cell death and microgliosis in mouse brain","volume":"40","author":"Brionne","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.nbd.2008.01.007","article-title":"TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway","volume":"30","author":"Caraci","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.euroneuro.2011.08.006","article-title":"The CC genotype of transforming growth factor-\u03b21 increases the risk of late-onset Alzheimer\u2019s disease and is associated with AD-related depression","volume":"22","author":"Caraci","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2009.10.022","article-title":"Depression and Alzheimer\u2019s disease: neurobiological links and common pharmacological targets","volume":"626","author":"Caraci","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.phrs.2018.02.007","article-title":"Neurobiological links between depression and AD: the role of TGF-\u03b21 signaling as a new pharmacological target","volume":"130","author":"Caraci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0075","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fphar.2016.00389","article-title":"Fluoxetine prevents A\u03b21-42-induced toxicity via a paracrine signaling mediated by transforming-growth-factor-\u03b21","volume":"7","author":"Caraci","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.809541","article-title":"Antioxidant activity of fluoxetine and vortioxetine in a non-transgenic animal model of Alzheimer\u2019s disease","volume":"12","author":"Caruso","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.neuroscience.2025.09.010_b0085","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1017\/S0317167100005606","article-title":"Assessment of behavioural and psychological symptoms associated with dementia","volume":"34","author":"Conn","year":"2007","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0090","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1096\/fasebj.13.15.2225","article-title":"Mitotic signaling by beta-amyloid causes neuronal death","volume":"13","author":"Copani","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0095","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1017\/S003329172200397X","article-title":"Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance","volume":"53","author":"Costello","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1471-4159.2010.06622.x","article-title":"Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity","volume":"113","author":"Counts","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbr.2016.08.005","article-title":"Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression","volume":"316","author":"Dall\u00e9","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0110","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1046\/j.1460-9568.2002.02283.x","article-title":"Neuro-glia interaction effects on GFAP gene: a novel role for transforming growth factor-beta1","volume":"16","author":"de Sampaio e Spohr","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0531-5565(02)00018-9","article-title":"Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer\u2019s disease","volume":"37","author":"De Servi","year":"2002","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gps.2565","article-title":"Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer\u2019s disease study \u00b1 2 (DIADS-2)?","volume":"26","author":"Drye","year":"2011","journal-title":"Int. J. Geriat. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0135","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.amjmed.2018.04.029","article-title":"Nonanesthetic effects of ketamine: a review article","volume":"131","author":"Eldufani","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.trci.2019.11.007","article-title":"Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer\u2019s disease","volume":"5","author":"Fessel","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0145","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1212\/WNL.45.8.1561","article-title":"Altered expression of transforming growth factor-beta in Alzheimer\u2019s disease","volume":"45","author":"Flanders","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0150","doi-asserted-by":"crossref","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, Brendel, M., Sauerbeck, J., Greven, S., Kotz, S., Scheiwein, F., Blautzik, J., Delker, A., Pogarell, O., Ishii, K., Bartenstein, P., Rominger, A., 2018. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer\u2019s Disease Patients with Depressive Symptoms. JAD. 65 793\u2013806. DOi: 10.3233\/JAD-170387.","DOI":"10.3233\/JAD-170387"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0047-6374(03)00025-3","article-title":"Plasma cytokine profiles in elderly humans","volume":"124","author":"Forsey","year":"2003","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jad.2006.01.018","article-title":"Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy","volume":"91","author":"Gallassi","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","article-title":"Vortioxetine: a novel antidepressant for the treatment of major depressive disorder","volume":"14","author":"Gonda","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0170","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/antiox10071075","article-title":"Improving cognition with nutraceuticals targeting TGF-\u03b21 signaling","volume":"10","author":"Grasso","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0175","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4103\/1673-5374.293147","article-title":"Glial-derived transforming growth factor \u03b21 (TGF-\u03b21): a key factor in multiple sclerosis neuroinflammation","volume":"16","author":"Guevara","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0180","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1038\/s44319-025-00470-0","article-title":"Elevated TGF-\u03b21 impairs synaptic and cognitive function through activation of Smad2\/3-Sp1 pathway in AngII-related hypertension","volume":"26","author":"Guo","year":"2025","journal-title":"EMBO Rep."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.2051-5545.2010.tb00298.x","article-title":"Pathophysiology of depression: do we have any solid evidence of interest to clinicians?","volume":"9","author":"Hasler","year":"2010","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0195","doi-asserted-by":"crossref","first-page":"11602","DOI":"10.3390\/ijms222111602","article-title":"Fluoroquinolones suppress TGF-\u03b2 and PMA-induced MMP-9 production in cancer cells: implications in repurposing quinolone antibiotics for cancer treatment","volume":"22","author":"Huang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.21101\/cejph.a4414","article-title":"Is mild cognitive impairment a precursor of Alzheimer\u2019s disease? Short review","volume":"23","author":"Janoutov\u00e1","year":"2015","journal-title":"Cent. Eur. J. Public Health"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0205","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1007\/s12035-016-9952-9","article-title":"Long-term ameliorative effects of the antidepressant fluoxetine exposure on cognitive deficits in 3\u2009\u00d7\u2009TgAD mice","volume":"54","author":"Jin","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0210","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241258473","article-title":"Is there evidence for using ketamine among individuals with dementia?","volume":"52","author":"Kapoor","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109325","article-title":"Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants","volume":"223","author":"Kato","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0220","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/jnnp.2003.031773","article-title":"Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?","volume":"75","author":"Kessing","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72878-8","article-title":"Cerebrospinal fluid sTREM2 in Alzheimer\u2019s disease: comparisons between clinical presentation and AT classification","volume":"10","author":"Knapskog","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0230","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/521754","article-title":"Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells","volume":"2014","author":"Krstic","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0235","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004714-200104000-00012","article-title":"Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma\/interleukin-10 production ratio","volume":"21","author":"Kubera","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0240","doi-asserted-by":"crossref","unstructured":"Kubera, M., Maes, M., 2000. Serotonin-Immune Interactions in Major Depression. In: Patterson, P., Kordon, C., Christen, Y. (Eds.), Neuro-Immune Interactions in Neurologic and Psychiatric Disorders, Research and Perspectives in Neurosciences. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 79\u201387. DOi: 10.1007\/978-3-642-59643-8_8.","DOI":"10.1007\/978-3-642-59643-8_8"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0245","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1586\/14737175.2.6.849","article-title":"SNRIs: mechanism of action and clinical features","volume":"2","author":"Lambert","year":"2002","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0250","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1017\/S1461145713000485","article-title":"Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression","volume":"16","author":"Lara","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0255","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.intimp.2006.03.015","article-title":"The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder","volume":"6","author":"Lee","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0260","first-page":"2468","article-title":"TGF-\u03b2 signaling in microglia: a key regulator of development","volume":"12","author":"Li","year":"2024","journal-title":"Homeostasis and Reactivity. Biomedicines"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0265","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2020.00279","article-title":"Pathways connecting late-life depression and dementia","volume":"11","author":"Linnemann","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-024-03163-y","article-title":"Tracking neuroinflammatory biomarkers in Alzheimer\u2019s disease: a strategy for individualized therapeutic approaches?","volume":"21","author":"Lista","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0275","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JAD-141062","article-title":"Norepinephrine protects against Amyloid-\u03b2 Toxicity via TrkB","volume":"44","author":"Liu","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0280","first-page":"47","article-title":"The anti-inflammatory effects of ketamine: state of the art","volume":"62","author":"Loix","year":"2011","journal-title":"Acta Anaesthesiol. Belg."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0285","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/biomedicines10051206","article-title":"TGF-\u03b2 as a key modulator of astrocyte reactivity: disease relevance and therapeutic implications","volume":"10","author":"Luo","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0290","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archneur.57.8.1153","article-title":"Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia","volume":"57","author":"Luterman","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0295","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41398-022-02192-6","article-title":"A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice","volume":"12","author":"Ma","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-0-585-37970-8_2","article-title":"Major depression and activation of the inflammatory response system","volume":"461","author":"Maes","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41572-023-00454-1","article-title":"Major depressive disorder","volume":"9","author":"Marx","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0310","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/medicina58010060","article-title":"YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer\u2019s disease","volume":"58","author":"Mavroudis","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0320","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-03851-3","article-title":"Antidepressant use and cognitive decline in patients with dementia: a national cohort study","volume":"23","author":"Mo","year":"2025","journal-title":"BMC Med."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0325","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.61.8.1290","article-title":"Depression in patients with mild cognitive impairment increases the risk of developing dementia ofAalzheimer type: a prospective cohort study","volume":"61","author":"Modrego","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0330","article-title":"Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation","volume":"5","author":"Morgan","year":"2014","journal-title":"Front. Psych."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0b013e31802e0002","article-title":"Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment?: A double-blind, placebo-controlled, clinical trial","volume":"27","author":"Mowla","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0340","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-013-3255-x","article-title":"Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response","volume":"231","author":"Murrough","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0345","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jad.2011.05.047","article-title":"Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression\u2013no influence of celecoxib treatment","volume":"134","author":"Musil","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0350","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2005.07.008","article-title":"Th1, Th2, and Th3 cytokine alterations in major depression","volume":"88","author":"Myint","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0355","first-page":"43","article-title":"Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses","volume":"15","author":"Nasb","year":"2024","journal-title":"Aging Dis."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0360","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1523\/JNEUROSCI.15-11-07539.1995","article-title":"Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments","volume":"15","author":"Nibuya","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0365","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits","volume":"77","author":"Niesters","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0370","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41597-024-03538-z","article-title":"Molecular signatures of premature aging in major depression and substance use disorders","volume":"11","author":"Onisiforou","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0375","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis","volume":"63","author":"Ownby","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0380","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JAD-2010-1352","article-title":"Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer\u2019s disease: the role of depression and apathy","volume":"20","author":"Palmer","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0385","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/1060028014528305","article-title":"Vortioxetine for the treatment of depression","volume":"48","author":"Pearce","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0395","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0197-4580(96)00115-7","article-title":"Inflammation and Alzheimer\u2019s disease pathogenesis","volume":"17","author":"Rogers","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arcmed.2007.10.001","article-title":"Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer\u2019s disease","volume":"39","author":"Rojo","year":"2008","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0405","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","article-title":"Sertraline for the treatment of depression in Alzheimer disease","volume":"18","author":"Rosenberg","year":"2010","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0410","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3389\/fimmu.2019.01167","article-title":"Structural modification of the antidepressant Mianserin suggests that its anti-inflammatory activity may be independent of 5-hydroxytryptamine receptors","volume":"10","author":"Sacre","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0415","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pnpbp.2004.11.003","article-title":"Cytokines and major depression","volume":"29","author":"Schiepers","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0420","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/biomedicines11010214","article-title":"TGF-beta modulates the integrity of the blood brain barrier in vitro, and is associated with metabolic alterations in pericytes","volume":"11","author":"Schumacher","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0425","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamapsychiatry.2014.2427","article-title":"Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes","volume":"72","author":"Setiawan","year":"2015","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0430","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S1461145714001011","article-title":"Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression","volume":"17","author":"Shiroma","year":"2014","journal-title":"Int. J. Neuropsychopharm."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0435","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fnagi.2019.00186","article-title":"Ketamine: a neglected therapy for Alzheimer disease","volume":"11","author":"Smalheiser","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0440","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/jnr.1229","article-title":"Transforming growth factor-beta1 enhances expression of brain-derived neurotrophic factor and its receptor, TrkB, in neurons cultured from rat cerebral cortex","volume":"66","author":"Sometani","year":"2001","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.825729","article-title":"Promoter hypomethylation of TGFBR3 as a risk factor of Alzheimer\u2019s disease: an integrated epigenomic-transcriptomic analysis","volume":"9","author":"Song","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0450","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846171","article-title":"Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures","volume":"19","author":"Sousa","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0455","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/HRP.0000000000000312","article-title":"Neurocognitive effects of ketamine and Esketamine for treatment-resistant major depressive disorder: a systematic review","volume":"29","author":"Souza-Marques","year":"2021","journal-title":"Harv. Rev. Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.neuroscience.2025.09.010_b0460","first-page":"5","article-title":"Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action","volume":"59","author":"Stahl","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.110820","article-title":"The relationship between TGF-\u03b21 and cognitive function in the brain","volume":"205","author":"Su","year":"2023","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0470","doi-asserted-by":"crossref","first-page":"76396","DOI":"10.1155\/2007\/76396","article-title":"Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy","volume":"2007","author":"Sutcigil","year":"2007","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0475","first-page":"353","article-title":"In vitro immunoregulatory effects of antidepressants in healthy volunteers","volume":"55","author":"Szuster-Ciesielska","year":"2003","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0480","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-065X.2012.01127.x","article-title":"Inflammatory cell trafficking across the blood\u2013brain barrier: chemokine regulation and in vitro models","volume":"248","author":"Takeshita","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0485","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1365-2990.1998.00117.x","article-title":"Differential expression of transforming growth factor-beta isoforms in human prion diseases","volume":"24","author":"Tashiro","year":"1998","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0490","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.tibs.2004.03.008","article-title":"New insights into TGF-beta-Smad signalling","volume":"29","author":"ten Dijke","year":"2004","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0495","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1172\/JCI27341","article-title":"Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer\u2019s pathology","volume":"116","author":"Tesseur","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0500","doi-asserted-by":"crossref","DOI":"10.1155\/nri\/8948290","article-title":"Inhibition of the transforming growth factor-\u03b2 signaling pathway confers neuroprotective effects on beta-amyloid-induced direct neurotoxicity and microglia-mediated neuroinflammation","volume":"2025","author":"Tiong","year":"2025","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0505","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fphar.2019.00693","article-title":"Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by A\u03b21-42 oligomers in mice: a key role of transforming growth factor-\u03b21","volume":"10","author":"Torrisi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0510","first-page":"1135","article-title":"TGF-beta1 and IL-6 expression in rat pineal gland is regulated by norepinephrine and interleukin-1beta","volume":"16","author":"Tsai","year":"2001","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2024.137836","article-title":"Esketamine induces tripartite motif-containing protein 24 to improve cognitive dysfunction in Alzheimer\u2019s disease","volume":"834","author":"Tu","year":"2024","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0520","doi-asserted-by":"crossref","DOI":"10.1017\/S1461145707007729","article-title":"Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model","volume":"11","author":"Vollmar","year":"2008","journal-title":"Int. J. Neuropsychopharm."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0525","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s40001-024-02006-z","article-title":"Efficacy of selective serotonin reuptake inhibitors-related antidepressants in Alzheimer\u2019s disease: a meta-analysis","volume":"29","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0530","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2174\/1567205011666140812114715","article-title":"Fluoxetine improves behavioral performance by suppressing the production of soluble \u03b2-amyloid in APP\/PS1 mice","volume":"11","author":"Wang","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0535","doi-asserted-by":"crossref","first-page":"19454","DOI":"10.1038\/s41598-022-23477-2","article-title":"Single-cell transcriptomics defines an improved, validated monoculture protocol for differentiation of human iPSC to microglia","volume":"12","author":"Washer","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0540","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0545","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euroneuro.2021.04.010","article-title":"Intranasal administration of transforming growth factor-\u03b21 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: a role of TrkB signaling","volume":"50","author":"Wei","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/156720506777632916","article-title":"Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer\u2019s","volume":"3","author":"Wyss-Coray","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0555","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/87945","article-title":"TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice","volume":"7","author":"Wyss-Coray","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0560","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/39321","article-title":"Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer\u2019s disease","volume":"389","author":"Wyss-Coray","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0565","doi-asserted-by":"crossref","first-page":"17329","DOI":"10.3390\/ijms242417329","article-title":"TGF-\u03b21 decreases microglia-mediated neuroinflammation and lipid droplet accumulation in an in vitro stroke model","volume":"24","author":"Xin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0570","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jad.2024.08.222","article-title":"Effects of arketamine on depression-like behaviors and demyelination in mice exposed to chronic restrain stress: a role of transforming growth factor-\u03b21","volume":"367","author":"Xu","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0575","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neulet.2013.04.016","article-title":"Ketamine reduces amyloid \u03b2-protein degradation by suppressing neprilysin expression in primary cultured astrocytes","volume":"545","author":"Yamamoto","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0580","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/gps.4409","article-title":"High amyloid-\u03b2 deposition related to depressive symptoms in older individuals with normal cognition: a pilot study","volume":"31","author":"Yasuno","year":"2016","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0585","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2011.07.006","article-title":"Pro- and anti-inflammatory cytokines expression in rat\u2019s brain and spleen exposed to chronic mild stress: involvement in depression","volume":"225","author":"You","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1047778","article-title":"Blood\u2013brain barrier endothelial cells in neurodegenerative diseases: signals from the \u201cbarrier.","volume":"17","author":"Yuan","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0595","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2016.03.011","article-title":"Venlafaxine treatment after endothelin-1-induced cortical stroke modulates growth factor expression and reduces tissue damage in rats","volume":"107","author":"Zepeda","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0605","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0610","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bpsgos.2021.04.002","article-title":"(R,S)-ketamine promotes striatal neurogenesis and sensorimotor recovery through improving poststroke depression\u2013mediated decrease in atrial natriuretic peptide","volume":"1","author":"Zhang","year":"2021","journal-title":"Biological Psychiatry Global Open Science"},{"key":"10.1016\/j.neuroscience.2025.09.010_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177096","article-title":"Transforming growth factor-\u03b21 mediates the beneficial effects of arketamine on demyelination and remyelination in the brains of cuprizone-treated mice","volume":"985","author":"Zhao","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0620","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jad.2018.12.005","article-title":"Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder","volume":"246","author":"Zheng","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuroscience.2025.09.010_b0625","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1176\/appi.ajp.160.5.857","article-title":"A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer\u2019s disease","volume":"160","author":"Zubenko","year":"2003","journal-title":"Am. J. Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.neuroscience.2025.12.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000}}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645222500925X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645222500925X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T20:47:28Z","timestamp":1758833248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030645222500925X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":125,"alternative-id":["S030645222500925X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.09.010","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the TGF-\u03b21 pathway in Alzheimer\u2019s disease and depression: Possible restoration potential of antidepressants","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}